Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do’s and Don’ts from the ECCO-COVID Taskforce

DOI PDF PDF 1 Citations
  • F Magro
    Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; Department of Gastroenterology, Centro Hospitalar de São João, Porto, Portugal; Department of Clinical Pharmacology Centro Hospitalar de São João, Porto, Portugal
  • J-F Rahier
    CHU UCL Namur, Université catholique de Louvain, service de Hépato-gastroentérologie, Yvoir, Belgium
  • C Abreu
    Infectious Diseases Service, Centro Hospitalar Universitário São João, Porto, Portugal; Instituto de Inovação e Investigação em Saúde (I3s), Faculty of Medicine, Department of Medicine, University of Porto, Portugal
  • E MacMahon
    Department of Infectious Diseases, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • A Hart
    IBD Unit, St Mark’s Hospital, London, UK
  • C J van der Woude
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlnads
  • H Gordon
    Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UKCentre for Immunobiology, The Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
  • M Adamina
    Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland
  • N Viget
    Department of Infectious Diseases, Tourcoing Hospital, Tourcoing, France
  • S Vavricka
    Center for Gastroenterology and Hepatology, Zürich, Switzerland
  • T Kucharzik
    Lüneburg Hospital, University of Hamburg, Department of Gastroenterology, Lüneburg, Germany
  • S Leone
    EFCCA, European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium
  • B Siegmund
    Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany
  • S Danese
    IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy
  • L Peyrin-Biroulet
    Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France

Description

<jats:title>Abstract</jats:title><jats:p>Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and on appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as inflammatory bowel disease [IBD]. In this review, we have compiled existing evidence on the impact of COVID-19 in IBD patients and provide guidance on the most appropriate care to adopt during the pandemic. Our review highlights that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management should be carefully adapted: [i] in SARS-CoV-2-positive IBD patients, medical treatments should be re-evaluated [with a particular focus on corticosteroids] always with the purpose of treating active disease and maintaining remission; [ii] non-urgent surgeries and endoscopic procedures should be postponed for all patients; [iii] online consultancy should be implemented; and [iv] hospitalization and surgery should be limited to life-threatening situations.</jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top